• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    1/16/24 4:37:18 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRX alert in real time by email
    SC 13G/A 1 zeskind-2024schedule13game.htm SC 13G/A Document

    image_5.jpg
    Securities and Exchange Commission

    Washington, D.C. 20549

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant
    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

    Immuneering Corporation
    (Name of Issuer)

    Class A Common Stock
    (Title of Class of Securities)

    45254E107
    (CUSIP Number)

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    image_5.jpg



    CUSIP No. 45254E107Schedule 13GPage 1 of 4
    image_5.jpg

    1Names of Reporting Persons

    Benjamin J. Zeskind

    image_5.jpg

    2    Check the Appropriate Box if a Member of a Group
    (a) ☐
    (b) ☐
    image_5.jpg

    3SEC Use Only

    image_5.jpg


    4Citizenship or Place of Organization

    United States
    image_5.jpg

    5
    Sole Voting Power
    2,792,215
    6
    Shared Voting Power
    Number of Shares894,927
    Beneficially Owned
    by Each Reporting
    7
    Sole Dispositive Power
    Person With
    2,792,215
    8
    Shared Dispositive Power
    894,927


    image_5.jpg

    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,687,142
    image_5.jpg

    10    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    Not Applicable
    image_5.jpg

    11    Percent of Class Represented by Amount in Row 9

    12.6%
    image_5.jpg

    12Type of Reporting Person

    IN
    image_5.jpg





    CUSIP No. 45254E107Schedule 13GPage 2 of 4

    ITEM 1.    (a)    Name of Issuer:

    Immuneering Corporation (the “Issuer”).

    (b)Address of Issuer’s Principal Executive Offices:

    245 Main St., Second Floor, Cambridge, MA 02142

    ITEM 2.    (a)    Name of Person Filing:

    This statement is filed on behalf of Benjamin J. Zeskind (the “Reporting Person”).

    (b)Address or Principal Business Office:

    The principal business address of the Reporting Person is c/o Immuneering Corporation, 245 Main St., Second Floor, Cambridge, MA 02142.

    (c)Citizenship of each Reporting Person is:

    The Reporting Person is a citizen of the United States.

    (d)Title of Class of Securities:

    Class A common stock, par value $0.001 per share (“Class A Common Stock”).

    (e)CUSIP Number:

    45254E107

    ITEM 3.

    Not applicable.

    ITEM 4.    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of the shares of Class A Common Stock of the Issuer as of December 31, 2023, based upon 29,269,121 shares of Class A Common Stock outstanding as of October 31, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.
    image_5.jpg



    CUSIP No. 45254E107Schedule 13GPage 3 of 4
    Reporting Person
    Amount Beneficially owned:
    Percent of class:
    Sole power to vote or to direct the vote:
    Shared power to vote or to direct the vote:
    Sole power to dispose or to direct the disposition of:
    Shared power to dispose or to direct the disposition of:
    Benjamin J. Zeskind
    3,687,142
    12.6%2,792,215
    894,927
    2,792,215894,927

    The Reporting Person is the beneficial owner of 3,687,142 shares of Class A Common Stock, which consist of (i) 2,261,852 shares of Class A Common Stock held of record by the Reporting Person; (ii) 530,363 shares of Class A Common Stock underlying stock options held of record by the Reporting Person that are exercisable on or prior to February 29, 2024; and (iii) 894,927 shares of Class A Common Stock held of record by the Benjamin J. Zeskind 2020 Family Trust, of which the Reporting Person’s spouse serves as sole trustee.

    ITEM 5.    Ownership of Five Percent or Less of a Class.

    Not applicable.

    ITEM 6.    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    ITEM 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    ITEM 8.    Identification and Classification of Members of the Group.

    Not applicable.

    ITEM 9.    Notice of Dissolution of Group.

    Not applicable.

    ITEM 10.    Certification.

    Not applicable.
    image_5.jpg





    CUSIP No. 45254E107Schedule 13GPage 4 of 4

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: January 16, 2024

    Benjamin J. Zeskind

    /s/ Benjamin J. Zeskind


    Get the next $IMRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRX

    DatePrice TargetRatingAnalyst
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    3/15/2024$20.00 → $15.00Buy
    Needham
    3/15/2024Outperform → Market Perform
    TD Cowen
    3/15/2024$16.00 → $3.00Buy → Hold
    Jefferies
    12/1/2023$20.00Buy
    Needham
    6/26/2023$25.00Outperform
    Oppenheimer
    4/19/2023$5.00 → $14.00Underweight → Equal-Weight
    Morgan Stanley
    4/19/2023$10.00 → $20.00Neutral → Buy
    Mizuho
    More analyst ratings

    $IMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Morales Mallory bought $1,917 worth of shares (300 units at $6.39), increasing direct ownership by 1% to 27,533 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    10/2/25 9:02:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R bought $5,103 worth of shares (800 units at $6.38), increasing direct ownership by 4% to 23,344 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    10/2/25 8:57:31 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER, SECRETARY Bookman Michael bought $6,966 worth of shares (1,020 units at $6.83), increasing direct ownership by 26% to 4,870 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    10/2/25 8:52:43 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immuneering Corporation downgraded by Morgan Stanley

    Morgan Stanley downgraded Immuneering Corporation from Equal-Weight to Underweight

    12/13/24 8:04:38 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on Immuneering Corporation with a new price target

    Needham reiterated coverage of Immuneering Corporation with a rating of Buy and set a new price target of $15.00 from $20.00 previously

    3/15/24 7:50:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation downgraded by TD Cowen

    TD Cowen downgraded Immuneering Corporation from Outperform to Market Perform

    3/15/24 7:19:50 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Morales Mallory bought $1,917 worth of shares (300 units at $6.39), increasing direct ownership by 1% to 27,533 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    10/2/25 9:02:58 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Neufeld Leah R bought $5,103 worth of shares (800 units at $6.38), increasing direct ownership by 4% to 23,344 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    10/2/25 8:57:31 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER, SECRETARY Bookman Michael bought $6,966 worth of shares (1,020 units at $6.83), increasing direct ownership by 26% to 4,870 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    10/2/25 8:52:43 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    SEC Filings

    View All

    SEC Form 424B5 filed by Immuneering Corporation

    424B5 - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:26:30 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Immuneering Corp (0001790340) (Filer)

    9/25/25 5:23:28 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Immuneering Corporation

    FWP - Immuneering Corp (0001790340) (Subject)

    9/25/25 6:01:41 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

    NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering's Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 2,843,987 shares of Class A common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from t

    9/25/25 12:08:31 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

    NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of shares of its Class A common stock or, in lieu of Class A common stock, pre-funded warrants to purchase Class A common stock (the "Offering"). In addition, Immuneering intends to grant the underwriters a 30-day option to purchase up to a number of additional shares of Class A common stock equal to fifteen percent (15%) of the shares of Class A common stock and pre-funded warrants initially offered in the Offering. Immuneering also announced that Sanofi has entered into a sec

    9/24/25 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Leadership Updates

    Live Leadership Updates

    View All

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

    - Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE

    5/7/24 4:05:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

    CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization

    3/12/24 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Financials

    Live finance-specific insights

    View All

    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up. "These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed durin

    9/26/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory feedback on pivotal trial plans in Q4 2025 and, subject to that feedback, expects to initiate pivotal trial by the end of 2025 and begin dosing patients by mid-2026 - NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcita

    9/24/25 4:01:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

    - Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep Cyclic Inhibitors at the 7th RAS-Targeted Drug Development Summit - CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today shared plans to announce updated overall survival data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up on Thursday, September 25, 2025. Th

    9/10/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    4/15/24 6:10:57 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care